Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.

 

Category: Disaster

NIH Resource: The COVID-19 Treatment Guidelines Panel’s Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints

The COVID-19 Treatment Guidelines Panel (the Panel) has recommended several therapeutic agents for the treatment and prevention of SARS-CoV-2 infection in individuals who are at high risk for progression to severe COVID-19. These anti-SARS-CoV-2 therapeutics are of greatest be...

CDC Resources: Epidemiology-Outcomes

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Epidemiology-Outcomes

   Estimated Time: Coronavirus, COVID-19, Statistics

Mini-Bronchoalveolar Lavage for Diagnosing Coronavirus Disease 2019–Associated Invasive Pulmonary Aspergillosis

Critical Care Explorations  The authors found a similar percentage of positive test results in mini-bronchoalveolar lavage and bronchoalveolar lavage samples in patients with suspected coronavirus disease 2019–associated pulmonary aspergillosis, indicating that mini-bronchoalv...

   Estimated Time: 10:48 min Coronavirus, COVID-19, Diagnosis and Testing

Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019

Critical Care Explorations  In this study, the authors concluded that soluble CD14 subtype levels may have prognostic utility in coronavirus disease 2019.

   Estimated Time: 25:15 min Coronavirus, COVID-19, Statistics

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia

From Critical Care Medicine  The authors review the pathogenesis, clinical presentation, diagnosis, and treatment of vaccine-induced immune thrombotic thrombocytopenia, an unexpected consequence of the coronavirus disease 2019 pandemic era. 

   Estimated Time: 16:06 min Coronavirus, COVID-19, Vaccines

Assessment of 28-Day In-Hospital Mortality in Mechanically Ventilated Patients With Coronavirus Disease 2019: An International Cohort Study

From Critical Care Explorations  This international study suggests that in patients with coronavirus disease 2019 on invasive mechanical ventilation, older age and clinically relevant variables monitored at baseline or sequentially during the course of invasive mechanical vent...

   Estimated Time: 31:48 min Coronavirus, COVID-19, Ventilatory Support

Identification of Aggravation-Predicting Gene Polymorphisms in Coronavirus Disease 2019 Patients Using a Candidate Gene Approach Associated With Multiple Phase Pathogenesis: A Study in a Japanese City of 1 Million People

From Critical Care Explorations  In this observational study, the authors successfully identified significant genetic factors in OAS1 and IL1B genes using a candidate gene approach study as valuable information for further mechanistic investigation and predictive model building.

   Estimated Time: 25:10 min Coronavirus, COVID-19, Statistics

Caring for Unvaccinated Patients in the ICU: Beyond Frustration, Toward Beneficial Relationships

From Critical Care Explorations   In this essay, the authors propose a number of questions that recognize the existential frustrations critical care professionals experience when carting for unvaccinated patients in the ICU, while also uncovering the ethical obligations that r...

   Estimated Time: 11:17 min Coronavirus, COVID-19, Mental Health

Evaluation of Albumin Kinetics in Critically Ill Patients With Coronavirus Disease 2019 Compared to Those With Sepsis-Induced Acute Respiratory Distress Syndrome

From Critical Care Explorations  In this paper, the authors aimed to characterize the kinetics of serum albumin in critically ill patients with coronavirus disease 2019 compared with critically ill patients with sepsis-induced acute respiratory distress syndrome.

   Estimated Time: 13:31 min ARDS, Coronavirus, COVID-19, Sepsis

Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality

From Critical Care Explorations  This hypothesis-generating study suggests that the pathophysiology of immunothrombosis differs between coronavirus disease 2019 patients and noncoronavirus disease septic patients.

   Estimated Time: 30:14 min Coronavirus, COVID-19, DVT, Sepsis

Altered Heart Rate Variability Early in ICU Admission Differentiates Critically Ill Coronavirus Disease 2019 and All-Cause Sepsis Patients

From Critical Care Explorations  In this descriptive statistical study, heart rate variability measures were found to be statistically different across critically ill patients infected with severe acute respiratory syndrome coronavirus 2 and distinct from bacterial sepsis.

   Estimated Time: 28:50 min Cardiovascular, Coronavirus, COVID-19, Sepsis

One-Year Outcomes of Postintensive Care Syndrome in Critically Ill Coronavirus Disease 2019 Patients: A Single Institutional Study

From Critical Care Explorations  In this study, the authors found that Patients who suffered critical illness from coronavirus disease 2019 had a high frequency of postintensive care syndrome after 1 year. 

   Estimated Time: 25:16 min Coronavirus, COVID-19

WHO Resource: WHO Therapeutics and COVID-19: living guideline

The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via ...

   Estimated Time: Coronavirus, COVID-19, Therapies

AHA Resource: How a Bold, New Strategy Took on Health Care Inequities During the Pandemic (Blog)

AHA published a new blog post from an LLN member hospital titled,  The Pandemic. “How a Bold, New Strategy Took on Health Care Inequities During the Pandemic,” authored by Luminis Health Chief Diversity Officer Tamiko Stanley.  

FDA Resource: Paxlovid received EUA approval from the FDA

December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years o...

   Estimated Time: Coronavirus, COVID-19, Therapies

FDA Resource: Molnupiravir received EUA approval from the FDA

The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir sh...

   Estimated Time: Coronavirus, COVID-19, Therapies

ATS Resource: Critical Perspective: Bacterial Superinfection in Patients Mechanically Ventilated for COVID-19 Pneumonia (Podcast)

In this “Breathe Easy Critical Perspective” podcast, Dr. Dominique Pepper interviews Dr. Richard Wunderink They discuss Dr. Wunderink's recent publication in the Blue Journal about bacterial superinfection in patients intubated and mechanically ventilated for COVID-19 pneumoni...

AHA Resource: Nurse leaders discuss COVID-19 nursing challenges, solutions (Podcast)

The fourth and current wave of the COVID-19 pandemic has created a worrisome landscape for the nursing profession. Nurses across the country report that they no longer feel celebrated as heroes as they did in the early days of the pandemic. This AHA Podcast covers nurse leader...

   Estimated Time: Coronavirus, COVID-19, Mental Health

HHS Resource: Surgeon General Releases Community Toolkit for Addressing Health Misinformation

During the COVID-19 pandemic, people have been exposed to an abundance of information from a large number of sources.

   Estimated Time: Communication, Coronavirus, COVID-19

FDA News Release: FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns

On December 3, 2021, the U.S. Food and Drug Administration revised the emergency use authorization (EUA) of bamlanivimab and etesevimab (previously authorized for pediatric patients 12 years of age and older weighing at least 40 kilograms, or about 88 pounds), to additionally ...

   Estimated Time: Coronavirus, COVID-19, pediatrics